2022 -- H 7665  | |
========  | |
LC004902  | |
========  | |
STATE OF RHODE ISLAND  | |
IN GENERAL ASSEMBLY  | |
JANUARY SESSION, A.D. 2022  | |
____________  | |
A N A C T  | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT  | |
  | |
Introduced By: Representatives Noret, and Kazarian  | |
Date Introduced: March 02, 2022  | |
Referred To: House Health & Human Services  | |
It is enacted by the General Assembly as follows:  | |
1  | SECTION 1. Section 21-28-2.08 of the General Laws in Chapter 21-28 entitled "Uniform  | 
2  | Controlled Substances Act" is hereby amended to read as follows:  | 
3  | 21-28-2.08. Contents of schedules.  | 
4  | Schedule I  | 
5  | (a) Schedule I shall consist of the drugs and other substances, by whatever official name,  | 
6  | common or usual name, chemical name, or brand name designated, listed in this section.  | 
7  | (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the  | 
8  | following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers  | 
9  | whenever the existence of the isomers, esters, ethers, and salts is possible within the specific  | 
10  | chemical designation:  | 
11  | (1) Acetylmethadol  | 
12  | (2) Allylprodine  | 
13  | (3) Alphacetylmethadol  | 
14  | (4) Alphameprodine  | 
15  | (5) Alphamethadol  | 
16  | (6) Benzethidine  | 
17  | (7) Betacetylmethadol  | 
18  | (8) Betameprodine  | 
19  | (9) Betamethadol  | 
  | |
1  | (10) Betaprodine  | 
2  | (11) Clonitazene  | 
3  | (12) Dextromoramide  | 
4  | (13) Difenoxin  | 
5  | (14) Diampromide  | 
6  | (15) Diethylthiambutene  | 
7  | (16) Dimenoxadol  | 
8  | (17) Dimepheptanol  | 
9  | (18) Dimethylthiambutene  | 
10  | (19) Dioxaphetyl butyrate  | 
11  | (20) Dipipanone  | 
12  | (21) Ethylmethylthiambutene  | 
13  | (22) Etonitazene  | 
14  | (23) Extoxerdine  | 
15  | (24) Furethidine  | 
16  | (25) Hydroxypethidine  | 
17  | (26) Ketobemidone  | 
18  | (27) Levomoramide  | 
19  | (28) Levophenacylmorphan  | 
20  | (29) Morpheridine  | 
21  | (30) Noracymethadol  | 
22  | (31) Norlevorphanol  | 
23  | (32) Normethadone  | 
24  | (33) Norpipanone  | 
25  | (34) Phenadoxone  | 
26  | (35) Phenampromide  | 
27  | (36) Phenomorphan  | 
28  | (37) Phenoperidine  | 
29  | (38) Piritramide  | 
30  | (39) Proheptazine  | 
31  | (40) Properidine  | 
32  | (41) Propiram  | 
33  | (42) Racemoramide  | 
34  | (43) Trimeperidone  | 
  | LC004902 - Page 2 of 18  | 
1  | (44) Tilidine  | 
2  | (45) Alpha-methylfentanyl  | 
3  | (46) Beta-hydroxy-3-methylfentanyl other names:  | 
4  | N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl]-Nphenylpropanamide  | 
5  | (47) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-  | 
6  | phenylpropanamide)  | 
7  | (48) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical, positional, and  | 
8  | geometric isomers, salts and salts of isomers (Other names: acetyl fentanyl)  | 
9  | (49) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl] piperidin-4-yl]-N-phenyl propionamide  | 
10  | (Other names: beta-hydroxythiofentanyl)  | 
11  | (50) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide (Other names: Butyryl fentanyl)  | 
12  | (51) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (Other names: Furanyl  | 
13  | fentanyl)  | 
14  | (52) 3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl] benzamide (Other names:  | 
15  | AH-7921)  | 
16  | (53) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (Other names:  | 
17  | U-47700)  | 
18  | (54) 3-Methylbutyrfentanyl (Other names: 3-MBF)  | 
19  | (55) 4-Fluorobutyrfentanyl (Other names: 4-FBF, p-FBF)  | 
20  | (56) 4-Phenylfentanyl  | 
21  | (57) 4-Methoxybutyrfentanyl (Other names: 4-MeO-BF)  | 
22  | (58) Acrylfentanyl (Other names: acryloyfentanyl)  | 
23  | (59) Lofentanyl  | 
24  | (60) N-Methylcarfentanyl  | 
25  | (61) Ocfentanyl (INN, A-3217)  | 
26  | (63) 4-methoxymethylfentanyl (Other names: R-30490)  | 
27  | (64) 1-cyclohexyl-4-(1,2 diphenylethyl)piperazine) (Other names: MT-45, IC-6)  | 
28  | (c) Opium Derivatives. Unless specifically excepted or unless listed in another schedule,  | 
29  | any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the  | 
30  | existence of the salts, isomers, and salts of isomers is possible within the specific chemical  | 
31  | designation:  | 
32  | (1) Acetorphine  | 
33  | (2) Acetyldihydrocodeine  | 
34  | (3) Benzylmorphine  | 
  | LC004902 - Page 3 of 18  | 
1  | (4) Codeine methylbromide  | 
2  | (5) Codeine-N-Oxide  | 
3  | (6) Cyprenorphine  | 
4  | (7) Desomorphine  | 
5  | (8) Dihydromorphine  | 
6  | (9) Etorphine (Except hydrochloride salt)  | 
7  | (10) Heroin  | 
8  | (11) Hydromorphinol  | 
9  | (12) Methyldesorphine  | 
10  | (13) Methylihydromorphine  | 
11  | (14) Morphine methylbromide  | 
12  | (15) Morphine methylsulfonate  | 
13  | (16) Morphine-N-Oxide  | 
14  | (17) Myrophine  | 
15  | (18) Nococodeine  | 
16  | (19) Nicomorphine  | 
17  | (20) Normorphine  | 
18  | (21) Pholcodine  | 
19  | (22) Thebacon  | 
20  | (23) Drotebanol  | 
21  | (d) Hallucinogenic Substances. Unless specifically excepted or unless listed in another  | 
22  | schedule, any material, compound, mixture, or preparation that contains any quantity of the  | 
23  | following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers  | 
24  | whenever the existence of the salts, isomers, and salts of isomers is possible within the specific  | 
25  | chemical designation (for purposes of this subsection only, the term "isomer" includes the optical,  | 
26  | position, and geometric isomers):  | 
27  | (1) 3, 4-methylenedioxy amphetamine  | 
28  | (2) 5-methoxy-3, 4-methylenedioxy amphetamine  | 
29  | (3) 3, 4, 5-trimethoxy amphetamine  | 
30  | (4) Bufotenine  | 
31  | (5) Diethyltryptamine  | 
32  | (6) Dimethyltryptamine  | 
33  | (7) 4-methyl 2, 5-dimethoxyamphetamine  | 
34  | (8) Ibogaine  | 
  | LC004902 - Page 4 of 18  | 
1  | (9) Lysergic acid diethylamide  | 
2  | (10) Marihuana  | 
3  | (11) Mescaline  | 
4  | (12) Peyote. Meaning all parts of the plant presently classified botanically as Lophophora  | 
5  | Williamsii Lemair whether growing or not; the seeds of the plant; any extract from any part of the  | 
6  | plant; and any compound, manufacture, salt, derivative, mixture, or preparation of the plant, its  | 
7  | seeds or extracts.  | 
8  | (13) N-ethyl-3-piperidyl benzilate  | 
9  | (14) N-methyl-3-piperidyl benzilate  | 
10  | (15) Psilocybin  | 
11  | (16) Psilocyn  | 
12  | (17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the plant,  | 
13  | or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their  | 
14  | isomers with similar chemical structure and pharmacological activity such as the following: delta  | 
15  | 1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans  | 
16  | tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and  | 
17  | their optical isomer. (Since nomenclature of these substances is not internationally standardized,  | 
18  | compounds of these structures, regardless of numerical designation of atomic positions covered).  | 
19  | (18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2-  | 
20  | Thienyl analog of phencyclidine: TPCP  | 
21  | (19) 2,5 dimethoxyamphetamine  | 
22  | (20) 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha-  | 
23  | methylphenethyamine: 4-bromo-2,5-DMA  | 
24  | (21) 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine:  | 
25  | paramethoxyamphetamine: PMA  | 
26  | (22) Ethylamine analog of phencyclidine. N-ethyl-1-phenylcyclohexylamine, (1-  | 
27  | phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE  | 
28  | (23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)-pyrrolidine PCPy, PHP  | 
29  | (24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-  | 
30  | trimethyl-6H-dibenz o (b,d) pyran: Synhexyl.  | 
31  | (25) Salvia Divinorum (Salvinorin A or Divinorin A), meaning any extract from any part  | 
32  | of the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall  | 
33  | not mean the unaltered plant.  | 
34  | (26) Datura stamonium (jimsom weed or datura), meaning any extract from any part of the  | 
  | LC004902 - Page 5 of 18  | 
1  | plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall not mean  | 
2  | the unaltered plant.  | 
3  | (e) Depressants. Unless specifically excepted or unless listed in another schedule, any  | 
4  | material, compound, mixture, or preparation that contains any quantity of the following substances  | 
5  | having a depressant effect on the central nervous system, including its salts, isomers, and salts of  | 
6  | isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the  | 
7  | specific chemical designation:  | 
8  | (1) Mecloqualone.  | 
9  | (2) Methaqualone.  | 
10  | (3) 3-methyl fentanyl (n-(3methyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide.  | 
11  | (4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional, and geometric  | 
12  | isomers, salts, and salts of isomers.  | 
13  | (5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts  | 
14  | of isomers.  | 
15  | (6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts,  | 
16  | and salts of isomers.  | 
17  | (7) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl-alpha-  | 
18  | methylfentanyl), its optical isomers, salts, and salts of isomers.  | 
19  | (8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami de (alpha-  | 
20  | methylthiofentanyl), its optical isomers, salts, and salts of isomers.  | 
21  | (9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers,  | 
22  | salts, and salts of isomers.  | 
23  | (10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta-  | 
24  | hydroxyfentanyl), its optical isomers, salts, and salts of isomers.  | 
25  | (11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta-  | 
26  | hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers.  | 
27  | (12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro-panamide (3-  | 
28  | methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers.  | 
29  | (13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its  | 
30  | optical isomers, salts, and salts of isomers.  | 
31  | (14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical  | 
32  | isomers, salts, and salts of isomers.  | 
33  | (15) N-[1-(2-phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamid e (para-  | 
34  | fluorofentanyl), its optical isomers, salts, and salts of isomers.  | 
  | LC004902 - Page 6 of 18  | 
1  | (16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or  | 
2  | geometric isomers, salts, and salts of isomers.  | 
3  | (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any  | 
4  | material, compound, mixture, or preparation that contains any quantity of the following substances  | 
5  | having a stimulant effect on the central nervous system, including its salts, isomers, and salts of  | 
6  | isomers:  | 
7  | (1) Fenethylline  | 
8  | (2) N-ethylamphetamine  | 
9  | (3) 4-methyl-N-methylcathinone (Other name: mephedrone)  | 
10  | (4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone)  | 
11  | (5) 3,4-methylenedioxypyrovalerone (Other name: MDPV)  | 
12  | (g) Any material, compound, mixture, or preparation that contains any quantity of the  | 
13  | following substances:  | 
14  | (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)  | 
15  | (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol  | 
16  | (cannabicyclohexanol and CP-47,497 c8 homologue)  | 
17  | (3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073)  | 
18  | (4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)  | 
19  | (5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678)  | 
20  | (h) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical  | 
21  | compound which is not approved by the United States Food and Drug Administration or, if  | 
22  | approved, which is not dispensed or possessed in accordance with state and federal law, that  | 
23  | contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1-  | 
24  | Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1-  | 
25  | Pentyl-3-(1-naphthoyl) indole; dexanabinol (HU-211); or any compound in the following structural  | 
26  | classes:  | 
27  | (1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with  | 
28  | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,  | 
29  | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  | 
30  | group, whether or not further substituted in the indole ring to any extent and whether or not  | 
31  | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not  | 
32  | limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM-  | 
33  | 2201;  | 
34  | (2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with  | 
  | LC004902 - Page 7 of 18  | 
1  | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,  | 
2  | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  | 
3  | group whether or not further substituted in the indole ring to any extent and whether or not  | 
4  | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not  | 
5  | limited to, JWH-167, JWH-250, JWH-251, and RCS-8;  | 
6  | (3) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with  | 
7  | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,  | 
8  | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  | 
9  | group whether or not further substituted in the indole ring to any extent and whether or not  | 
10  | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not  | 
11  | limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;  | 
12  | (4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol  | 
13  | structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl,  | 
14  | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  | 
15  | group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural  | 
16  | class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol);  | 
17  | (5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl)  | 
18  | methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,  | 
19  | alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-  | 
20  | morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and  | 
21  | whether or not substituted in the naphthyl ring to any extent. Examples of this structural class  | 
22  | include, but are not limited to, JWH-175, JWH-184, and JWH-185;  | 
23  | (6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with  | 
24  | substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl,  | 
25  | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  | 
26  | group whether or not further substituted in the pyrrole ring to any extent and whether or not  | 
27  | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not  | 
28  | limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;  | 
29  | (7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene  | 
30  | structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,  | 
31  | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  | 
32  | group whether or not further substituted in the indene ring to any extent and whether or not  | 
33  | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not  | 
34  | limited to, JWH-176; or  | 
  | LC004902 - Page 8 of 18  | 
1  | (8) Any other synthetic cannabinoid or piperazine which is not approved by the United  | 
2  | States Food and Drug Administration or, if approved, which is not dispensed or possessed in  | 
3  | accordance with state and federal law.  | 
4  | (i) Synthetic cathinones. Unless specifically excepted, any chemical compound which is  | 
5  | not approved by the United States Food and Drug Administration or, if approved, which is not  | 
6  | dispensed or possessed in accordance with state and federal law, not including bupropion,  | 
7  | structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl,  | 
8  | naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or  | 
9  | more of the following ways:  | 
10  | (1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,  | 
11  | haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by  | 
12  | one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4-  | 
13  | Methylenedioxycathinone (bk-MDA);  | 
14  | (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this  | 
15  | class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone);  | 
16  | (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or  | 
17  | methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.  | 
18  | Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and α-  | 
19  | Pyrrolidinopropiophenone (α-PPP); or  | 
20  | (4) Any other synthetic cathinone which is not approved by the United States Food and  | 
21  | Drug Administration or, if approved, is not dispensed or possessed in accordance with state or  | 
22  | federal law.  | 
23  | Schedule II  | 
24  | (a) Schedule II shall consist of the drugs and other substances, by whatever official name,  | 
25  | common or usual name, chemical name, or brand name designated, listed in this section.  | 
26  | (b) Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or  | 
27  | unless listed in another schedule, any of the following substances whether produced directly or  | 
28  | indirectly by extraction from substances of vegetable origin, or independently by means of  | 
29  | chemical synthesis, or by a combination of extraction and chemical synthesis:  | 
30  | (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or  | 
31  | opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the  | 
32  | following:  | 
33  | (i) Raw opium  | 
34  | (ii) Opium extracts  | 
  | LC004902 - Page 9 of 18  | 
1  | (iii) Opium fluid extracts  | 
2  | (iv) Powdered opium  | 
3  | (v) Granulated opium  | 
4  | (vi) Tincture of opium  | 
5  | (vii) Etorphine hydrochloride  | 
6  | (viii) Codeine  | 
7  | (ix) Ethylmorphine  | 
8  | (x) Hydrocodone  | 
9  | (xi) Hydromorphone  | 
10  | (xii) Metopon  | 
11  | (xiii) Morphine  | 
12  | (xiv) Oxycodone  | 
13  | (xv) Oxymorphone  | 
14  | (xvi) Thebaine  | 
15  | (2) Any salt, compound, derivative, or preparation that is chemically equivalent or identical  | 
16  | with any of the substances referred to in subdivision (1) of this subsection, except that these  | 
17  | substances shall not include the isoquinoline alkaloids of opium.  | 
18  | (3) Opium poppy and poppy straw.  | 
19  | (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any  | 
20  | salt, compound, derivative, or preparation that is chemically equivalent or identical with any of  | 
21  | these substances, except that the substances shall not include decocainized coca leaves or extraction  | 
22  | of coca leaves, which extractions do not contain cocaine or ecgonine.  | 
23  | (5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or powder  | 
24  | form that contains the phenanthrine alkaloids of the opium poppy).  | 
25  | (c) Opiates. Unless specifically excepted or unless listed in another schedule, any of the  | 
26  | following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters, and ethers  | 
27  | whenever the existence of the isomers, esters, ethers, and salts is possible within the specific  | 
28  | chemical designation:  | 
29  | (1) Alphaprodine  | 
30  | (2) Anileridine  | 
31  | (3) Bezitramide  | 
32  | (4) Dihydrocodeine  | 
33  | (5) Diphenoxylate  | 
34  | (6) Fentanyl  | 
  | LC004902 - Page 10 of 18  | 
1  | (7) Isomethadone  | 
2  | (8) Levomethorphan  | 
3  | (9) Levorphanol  | 
4  | (10) Metazocine  | 
5  | (11) Methadone  | 
6  | (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane  | 
7  | (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic  | 
8  | acid  | 
9  | (14) Pethidine  | 
10  | (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine  | 
11  | (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate  | 
12  | (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid  | 
13  | (18) Phenaxocine  | 
14  | (19) Piminodine  | 
15  | (20) Racemethorphan  | 
16  | (21) Racemorphan  | 
17  | (22) Bulk Dextropropoxyphene (non-dosage forms)  | 
18  | (23) Suffentanil  | 
19  | (24) Alfentanil  | 
20  | (25) Levoalphacetylmethadol  | 
21  | (26) Carfentanil  | 
22  | (27) Remifentanil  | 
23  | (d) Stimulants. Unless specifically excepted or unless listed in another schedule, any  | 
24  | material, compound, mixture, or preparation that contains any quantity of the following substances  | 
25  | having a stimulant effect on the central nervous system:  | 
26  | (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers.  | 
27  | (2) Methamphetamine, its salts, and salts of its isomers.  | 
28  | (3) Phenmetrazine and its salts.  | 
29  | (4) Methylphenidate.  | 
30  | (e) Depressants. Unless specifically excepted or unless listed in another schedule, any  | 
31  | material, compound, mixture, or preparation that contains any quantity of the following substances  | 
32  | having a depressant effect on the central nervous system, including its salts, isomers, and salts of  | 
33  | isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the  | 
34  | specific chemical designation:  | 
  | LC004902 - Page 11 of 18  | 
1  | (1) Amobarbital  | 
2  | (2) Glutethimide  | 
3  | (3) Methyprylon  | 
4  | (4) Pentobarbital  | 
5  | (5) Phencyclidine  | 
6  | (6) Secobarbital  | 
7  | (7) Phencyclidine immediate precursors:  | 
8  | (i) 1-phencyclohexylamine  | 
9  | (ii) 1-piperidinocyclohexane-carbonitrile (PCC)  | 
10  | (8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some  | 
11  | other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone.  | 
12  | Schedule III  | 
13  | (a) Unless specifically excepted or unless listed in another schedule, any material,  | 
14  | compound, mixture, or preparation that contains any quantity of the following substances having a  | 
15  | depressant effect on the central nervous system:  | 
16  | (1) Any substance that contains any quantity of a derivative of barbituric acid or any salt  | 
17  | of a derivative of barbituric acid.  | 
18  | (2) Chlorhexadol  | 
19  | (3) Lysergic acid  | 
20  | (4) Lysergic acid amide  | 
21  | (5) Sulfondiethylmethane  | 
22  | (6) Sulfonethylmethane  | 
23  | (7) Sylfonmethane  | 
24  | (8) Any compound, mixture, or preparation containing amobarbital, secobarbital,  | 
25  | pentobarbital, or any salt of them and one or more other active medicinal ingredients that are not  | 
26  | listed in any schedule.  | 
27  | (9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or  | 
28  | any salt of any of these drugs and approved by the Food and Drug Administration for marketing  | 
29  | only as a suppository.  | 
30  | (10) Ketamine, its salts, isomers, and salts of isomers. (Some other names for ketamine:  | 
31  | (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone).  | 
32  | (b) Unless specifically excepted or unless listed in another schedule, any material,  | 
33  | compound, mixture, or preparation containing limited quantities of any of the following narcotic  | 
34  | drugs, or any salts of them:  | 
  | LC004902 - Page 12 of 18  | 
1  | (1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred  | 
2  | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal  | 
3  | or greater quantity of an isoquinoline alkaloid of opium.  | 
4  | (2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred  | 
5  | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or  | 
6  | more active, nonnarcotic ingredients in recognized therapeutic amounts.  | 
7  | (3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one  | 
8  | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with  | 
9  | a fourfold or greater quantity of an isoquinoline alkaloid of opium.  | 
10  | (4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one  | 
11  | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with  | 
12  | one or more active nonnarcotic ingredients in recognized therapeutic amounts.  | 
13  | (5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one hundred  | 
14  | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or  | 
15  | more active nonnarcotic ingredients in recognized therapeutic amounts.  | 
16  | (6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one hundred  | 
17  | milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with one or  | 
18  | more active nonnarcotic ingredients in recognized therapeutic amounts.  | 
19  | (7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred milliliters  | 
20  | (100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five milligrams (25 mgs.)  | 
21  | per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.  | 
22  | (8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters (100  | 
23  | mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in  | 
24  | recognized therapeutic amounts.  | 
25  | (c) Stimulants. Unless specifically excepted or listed in another schedule, any material,  | 
26  | compound, mixture, or preparation that contains any quantity of the following substances having a  | 
27  | stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers  | 
28  | whenever the existence of the salts of isomers is possible within the specific chemical designation:  | 
29  | (1) Benzphetamine  | 
30  | (2) Chlorphentermine  | 
31  | (3) Clortermine  | 
32  | (4) Mazindol  | 
33  | (5) Phendimetrazine  | 
34  | (d) Steroids and hormones. Anabolic steroids (AS) or human growth hormone (HGH),  | 
  | LC004902 - Page 13 of 18  | 
1  | excluding those compounds, mixtures, or preparations containing an anabolic steroid that because  | 
2  | of its concentration, preparation, mixture, or delivery system, has no significant potential for abuse,  | 
3  | as published in 21 C.F.R. § 1308.34, including, but not limited to, the following:  | 
4  | (1) Chlorionic Chorionic gonadotropin, except when used for injection or implantation in  | 
5  | cattle or any other nonhuman species and when that use is approved by the Food and Drug  | 
6  | Administration.  | 
7  | (2) Clostebol  | 
8  | (3) Dehydrochlormethyltestosterone  | 
9  | (4) Ethylestrenol  | 
10  | (5) Fluoxymesterone  | 
11  | (6) Mesterolone  | 
12  | (7) Metenolone  | 
13  | (8) Methandienone  | 
14  | (9) Methandrostenolone  | 
15  | (10) Methyltestosterone  | 
16  | (11) Nandrolone decanoate  | 
17  | (12) Nandrolone phenpropionate  | 
18  | (13) Norethandrolone  | 
19  | (14) Oxandrolone  | 
20  | (15) Oxymesterone  | 
21  | (16) Oxymetholone  | 
22  | (17) Stanozolol  | 
23  | (18) Testosterone propionate  | 
24  | (19) Testosterone-like related compounds  | 
25  | (20) Human Growth Hormone (HGH)  | 
26  | (e) Hallucinogenic substances.  | 
27  | (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in U.S.  | 
28  | Food and Drug Administration-approved drug product. (Some other names for dronabinol: (6aR-  | 
29  | trans)-6a, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo[b,d] pyra n-1-ol,or(-)-delta-  | 
30  | 9(trans)-tetrahydrocannabinol.)  | 
31  | Schedule IV  | 
32  | (1) Barbital.  | 
33  | (2) Chloral betaine  | 
34  | (3) Chloral hydrate  | 
  | LC004902 - Page 14 of 18  | 
1  | (4) Ethchrovynol  | 
2  | (5) Ethinamate  | 
3  | (6) Methohexital  | 
4  | (7) Meprobamate  | 
5  | (8) Methylphenobarbital  | 
6  | (9) Paraldehyde  | 
7  | (10) Petrichloral  | 
8  | (11) Phenobarbital  | 
9  | (12) Fenfluramine  | 
10  | (13) Diethylpropion  | 
11  | (14) Phentermine  | 
12  | (15) Pemoline (including organometallic complexes and chelates thereof).  | 
13  | (16) Chlordiazepoxide  | 
14  | (17) Clonazepam  | 
15  | (18) Clorazepate  | 
16  | (19) Diazepam  | 
17  | (20) Flurazepam  | 
18  | (21) Mebutamate  | 
19  | (22) Oxazepam  | 
20  | (23) Unless specifically excepted or unless listed in another schedule, any material,  | 
21  | compound, mixture, or preparation that contains any quantity of the following substances,  | 
22  | including its salts:  | 
23  | Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propronox  | 
24  | ybutane).  | 
25  | (24) Prazepam  | 
26  | (25) Lorazepam  | 
27  | (26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25)  | 
28  | micrograms of atropine sulfate per dosage unit.  | 
29  | (27) Pentazocine  | 
30  | (28) Pipradrol  | 
31  | (29) SPA (-)-1-dimethylamino-1, 2-diphenylethane  | 
32  | (30) Temazepam  | 
33  | (31) Halazepam  | 
34  | (32) Alprazolam  | 
  | LC004902 - Page 15 of 18  | 
1  | (33) Bromazepam  | 
2  | (34) Camazepam  | 
3  | (35) Clobazam  | 
4  | (36) Clotiazepam  | 
5  | (37) Cloxazolam  | 
6  | (38) Delorazepam  | 
7  | (39) Estazolam  | 
8  | (40) Ethyl Ioflazepate  | 
9  | (41) Fludizaepam  | 
10  | (42) Flunitrazepam  | 
11  | (43) Haloxazolam  | 
12  | (44) Ketazolam  | 
13  | (45) Loprazolam  | 
14  | (46) Lormetazepam  | 
15  | (47) Medazepam  | 
16  | (48) Nimetazepam  | 
17  | (49) Nitrazepam  | 
18  | (50) Nordiazepam  | 
19  | (51) Oxazolam  | 
20  | (52) Pinazepam  | 
21  | (53) Tetrazepam  | 
22  | (54) Mazindol  | 
23  | (55) Triazolam  | 
24  | (56) Midazolam  | 
25  | (57) Quazepam  | 
26  | (58) Butorphanol  | 
27  | (59) Sibutramine  | 
28  | Schedule V  | 
29  | (a) Any compound, mixture, or preparation containing any of the following limited  | 
30  | quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal  | 
31  | ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable  | 
32  | medicinal qualities other than those possessed by the narcotic drug alone:  | 
33  | (1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100  | 
34  | mls.) or per one hundred grams (100 gms.).  | 
  | LC004902 - Page 16 of 18  | 
1  | (2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 milliliters  | 
2  | (100 mls.) or per one hundred grams (100 gms.).  | 
3  | (3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 milliliters  | 
4  | (100 mls.) or per one hundred grams (100 gms.).  | 
5  | (4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less  | 
6  | than twenty-five (25) micrograms of atropine sulfate per dosage unit.  | 
7  | (5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred milliliters  | 
8  | (100 mls.) or per one hundred grams (100 gms.).  | 
9  | (b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than twenty-  | 
10  | five (25) micrograms of atropine sulfate per dosage unit.  | 
11  | (c) Buprenorphine  | 
12  | (d) Unless specifically exempted or excluded or unless listed in another schedule, any  | 
13  | material, compound, mixture, or preparation that contains any quantity of the following substances  | 
14  | having a stimulant effect on the central nervous system, including its salts, isomers, and salts of  | 
15  | isomers:  | 
16  | (1) Propylhexedrine (except as benzedrex inhaler)  | 
17  | (2) Pyrovalerone.  | 
18  | SECTION 2. This act shall take effect upon passage.  | 
========  | |
LC004902  | |
========  | |
  | LC004902 - Page 17 of 18  | 
EXPLANATION  | |
BY THE LEGISLATIVE COUNCIL  | |
OF  | |
A N A C T  | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT  | |
***  | |
1  | This act would authorize licensed veterinarians to control and prescribe chorionic  | 
2  | gonadotropin strictly for farm cattle treatments or any nonhuman species and when that use is  | 
3  | approved by the Food and Drug Administration.  | 
4  | This act would take effect upon passage.  | 
========  | |
LC004902  | |
========  | |
  | LC004902 - Page 18 of 18  |